Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2014-09-17

FDA Approved: DALIRESP — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

The FDA approved a supplemental application for Daliresp (roflumilast) submitted by AstraZeneca Pharmaceuticals LP. The action approves changes to the product's…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Daliresp (roflumilast)

Snippet

SUPPL AP for DALIRESP (ROFLUMILAST)